Lynparza (Olaparib) is considered medically necessary for patients with advanced
ovarian cancer and ALL of the following:
therapy with 3 or more lines of chemotherapy AND
concurrent therapy with other agents for the treatment of ovarian cancer.
Lynparza is considered medically necessary for the maintenance treatment of
recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in
patients who are in a complete or partial response to platinum-based
chemotherapy, as monotherapy.
Lynparza (Olaparib) is
considered medically necessary for patients with invasive breast cancer with the
1) HER-2 negative AND
2) BRCA-positive mutation
3) Prior therapy with
chemotherapy in the neoadjuvant, adjuvant, or metastatic setting AND
4) If HR-positive must
treatment with endocrine therapy OR
an inappropriate candidate therapy for endocrine therapy.